UroGen Pharma Ltd. (URGN)
43.25
-0.70
(-1.59%)
USD |
NASDAQ |
Sep 18, 16:00
43.30
+0.05
(+0.12%)
Pre-Market: 20:00
UroGen Pharma Enterprise Value : 2.200B for Sept. 18, 2026
Enterprise Value Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Enterprise Value Data
| Date | Value |
|---|---|
| September 18, 2026 | 2.200B |
| September 17, 2026 | 2.235B |
| September 16, 2026 | 2.212B |
| September 15, 2026 | 2.127B |
| September 14, 2026 | 2.171B |
| September 11, 2026 | 2.154B |
| September 10, 2026 | 2.151B |
| September 09, 2026 | 2.286B |
| September 08, 2026 | 2.228B |
| September 04, 2026 | 2.241B |
| September 03, 2026 | 2.280B |
| September 02, 2026 | 2.258B |
| September 01, 2026 | 2.207B |
| August 31, 2026 | 2.193B |
| August 28, 2026 | 2.219B |
| August 27, 2026 | 2.310B |
| August 26, 2026 | 2.332B |
| August 25, 2026 | 2.352B |
| August 24, 2026 | 2.343B |
| August 21, 2026 | 2.377B |
| August 20, 2026 | 2.374B |
| August 19, 2026 | 2.544B |
| August 18, 2026 | 2.478B |
| August 17, 2026 | 2.488B |
| August 14, 2026 | 2.443B |
| Date | Value |
|---|---|
| August 13, 2026 | 2.438B |
| August 12, 2026 | 2.481B |
| August 11, 2026 | 2.389B |
| August 10, 2026 | 2.350B |
| August 07, 2026 | 2.382B |
| August 06, 2026 | 2.315B |
| August 05, 2026 | 2.356B |
| August 04, 2026 | 2.038B |
| August 03, 2026 | 1.973B |
| July 31, 2026 | 1.956B |
| July 30, 2026 | 2.095B |
| July 29, 2026 | 2.064B |
| July 28, 2026 | 2.085B |
| July 27, 2026 | 2.113B |
| July 24, 2026 | 2.089B |
| July 23, 2026 | 2.164B |
| July 22, 2026 | 2.142B |
| July 21, 2026 | 2.226B |
| July 20, 2026 | 2.096B |
| July 17, 2026 | 2.053B |
| July 16, 2026 | 2.042B |
| July 15, 2026 | 2.032B |
| July 14, 2026 | 2.002B |
| July 13, 2026 | 2.018B |
| July 10, 2026 | 1.971B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Xencor, Inc. | 1.551B |
| MeiraGTx Holdings Plc | 1.217B |
| Insmed, Inc. | 25.78B |
| Ironwood Pharmaceuticals, Inc. | 1.038B |
| Viking Therapeutics, Inc. | 2.884B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -14.35M |
| Revenue (Quarterly) | 72.46M |
| Total Expenses (Quarterly) | 86.81M |
| EPS Diluted (Quarterly) | -0.2848 |
| Gross Profit Margin (Quarterly) | 90.93% |
| Profit Margin (Quarterly) | -19.81% |
| Earnings Yield | -4.61% |
| Normalized Earnings Yield | -4.610 |